What is Stem Cell PRP Therapy?
Stem Cell PRP Therapy, operating under the brand Relievus, is a specialized provider of regenerative medicine services, focusing on stem cell and platelet-rich plasma (PRP) therapies. The company aims to alleviate pain and promote healing for patients experiencing conditions such as arthritis. With a network of clinics across New Jersey and Pennsylvania, Relievus employs a multidisciplinary team of specialists, including pain management experts, neurologists, and physiatrists, to offer integrated treatment plans. Their approach leverages the body's inherent healing capabilities, positioning them as a key player in the evolving landscape of non-invasive pain relief and recovery.
How much funding has Stem Cell PRP Therapy raised?
Stem Cell PRP Therapy has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Stem Cell PRP Therapy
PPP
Public-Private Partnership
What's next for Stem Cell PRP Therapy?
The substantial late-stage funding indicates a strategic push for Stem Cell PRP Therapy to scale its operations, potentially expanding its clinic footprint and enhancing its service offerings. This capital injection is likely to fuel further research and development in regenerative therapies, solidifying its competitive edge. The company's focus on leveraging autologous healing elements positions it favorably to capitalize on the growing demand for effective, minimally invasive treatments in the pain management and orthopedic markets. Future developments may include broader adoption of their therapies and strategic partnerships to enhance patient access and outcomes.
See full Stem Cell PRP Therapy company page
